Prior authorization for biologic disease-modifying antirheumatic drugs: A description of US medicaid programs

Arthritis Care and Research

Volumn 59, Issue 11, 2008, Pages 1611-1617

  Fischer, Michael A ^a   Polinski, Jennifer M ^a   Servi, Amber D ^a   Agnew Blais, Jessica ^a   Kaci, Liljana ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG INFUSION; DRUG USE; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MEDICAID; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG UTILIZATION REVIEW; HEALTH POLICY; HUMANS; IMMUNOGLOBULIN G; MEDICAID; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; UNITED STATES;

EID: 56049086018     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24191     Document Type: Article

References (13)

1. Bruen B, Ghosh A. Medicaid prescription drug spending and use. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2004.
2. National Pharmaceutical Council. Pharmaceutical benefits under state medical assistance programs, 2005-2006. Reston (VA): National Pharmaceutical Council; 2006.
3. Mello MM, Studdert DM, Brennan TA. The pharmaceutical industry versus Medicaid: limits of state initiatives to control prescription-drug costs. N Engl J Med 2004;350:608-13.
4. Fischer MA, Cheng HC, Schneeweiss S, Avorn J, Solomon DH. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care 2006;44:658-63.
5. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin receptor blockers: can policy promote rational prescribing? Health Aff (Millwood) 2007;26:800-7.
6. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004;351:2187-94.
7. Fischer MA, Servi AD, Polinski JM, Wang PS. Restrictions for antidepressant medications in children: a review of Medicaid policy. Psychiatr Serv 2007;58:135-8.
8. Polinski JM, Wang PS, Fischer MA. Early effects of an FDA advisory regarding antipsychotic medications on US Medicaid prior authorization programs. Health Aff (Millwood) 2007;26:750-60.
9. Roughead EE, Zhang F, Ross-Degnan D, Soumerai S. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care 2006;44:378-82.
10. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612-7.
11. Tilly J, Elam L. Prior authorization for Medicaid prescription drugs in five states: lessons for policy makers. Washington, DC: Henry J. Kaiser Family Foundation; 2003.
12. CMS. State drug utilization data. URL: http://www.cms.hhs.gov/ MedicaidDrugRebateProgram/SDUD/list.asp#TopOfPage.
13. Stata statistical software: release 9.0. College Station (TX): Stata Corporation; 2005.